GSK and iTeos Therapeutics announce development and …
Jun 14, 2021 · GlaxoSmithKline plc (LSE/NYSE: GSK) and iTeos Therapeutics (NASD: ITOS) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT …
GSK axes $625M TIGIT drug as midphase data disappoint, …
6 days ago · London-based GSK paid iTeos $625 million upfront for rights to belrestotug four years ago. At the time, interest in TIGIT was riding high as Bristol Myers Squibb, Gilead …
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of
5 days ago · GSK and iTeos came together for this collaboration in 2021, in a deal that had GSK paying iTeos $625 up front and up to $1.45 billion in downstream milestone payments. …
ESMO: iTeos-GSK's TIGIT star shows meaningful improvement
Sep 14, 2024 · iTeos and GSK are launching their spaceship into another galaxy, touting phase 2 findings that prompted the late-stage GALAXIES Lung-301 trial.
GSK is the ideal partner with an approved PD-1, and a leading portfolio in the TIGIT-CD226 axis that will allow for multiple novel combinations. iTeos and GSK will co-commercialize and share …
GSK pays iTeos $625M upfront to join Merck, Roche and the rest …
Jun 14, 2021 · GlaxoSmithKline is paying iTeos Therapeutics $625 million upfront for rights to phase 1 anti-TIGIT monoclonal antibody EOS-448. The deal sets GSK up to challenge Bristol …
GSK, partner iTeos scrap development of lung cancer therapy
6 days ago · Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the …
GSK, iTeos take stock after Roche's TIGIT setback
5 days ago · The failure of Roche's tiragolumab in the SKYSCRAPER-01 trial in on-small cell lung cancer (NSCLC) has cast a pall over the TIGIT class, but iTeos said it is committed with GSK …
iTeos, GSK to shelve TIGIT drug after study setback
May 13, 2025 · GSK paid iTeos $625 million in guaranteed cash, and promised up to $1.45 billion more, for rights to belrestotug. In a statement at the time, GSK noted how combinations …
iTeos Therapeutics and GSK announce development and
Jun 14, 2021 · GSK and iTeos will co-commercialise and share profits in the US; GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation …
- Some results have been removed